Short answer
Rapport Therapeutics, Inc. (RAPP) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 with net income of −$57M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- −100.0% QoQ
- Net income
- −$57M
- −111.8% YoY · −185.1% QoQ
- EPS (diluted)
- −$1.19
- −56.6% YoY · −183.3% QoQ
Source: XBRL data from the Rapport Therapeutics, Inc. (RAPP) Q2 2026 10-Q on SEC EDGAR. USD.
Rapport Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly triggered financing risk: $150.0 million ATM program established under March 2026 Form S-3ASR
- Cash runway risk: $436.1 million available, projected to fund operations into second half of 2029
- Regulatory risk: FDA clinical hold previously delayed RAP-219 DPNP development until removal in December 2025
- Development risk: RAP-219 Phase 3 program underway for drug-resistant focal onset seizures
- Licensing risk: Janssen obligations include up to $76.0 million development milestones and $40.0 million sales milestones
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Rapport Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.